Dapagliflozin + Placebo
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Heart Failure, Diastolic
Conditions
Heart Failure, Diastolic
Trial Timeline
Jul 1, 2020 → May 1, 2022
NCT ID
NCT04475042About Dapagliflozin + Placebo
Dapagliflozin + Placebo is a phase 2 stage product being developed by AstraZeneca for Heart Failure, Diastolic. The current trial status is unknown. This product is registered under clinical trial identifier NCT04475042. Target conditions include Heart Failure, Diastolic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04792190 | Approved | Completed |
| NCT04869124 | Approved | Completed |
| NCT04564742 | Phase 3 | Completed |
| NCT04363697 | Approved | Completed |
| NCT04475042 | Phase 2 | UNKNOWN |
| NCT02981966 | Approved | Completed |
| NCT03619213 | Phase 3 | Completed |
| NCT03387683 | Approved | Completed |
| NCT02956811 | Approved | Completed |
| NCT03036124 | Phase 3 | Completed |
| NCT03036150 | Phase 3 | Completed |
| NCT02796170 | Approved | Completed |
| NCT02520518 | Phase 2 | Terminated |
| NCT02459353 | Approved | Completed |
| NCT02371187 | Phase 2 | Completed |
| NCT02426541 | Approved | Completed |
| NCT01392677 | Phase 3 | Completed |
| NCT01042977 | Phase 3 | Completed |
| NCT01031680 | Phase 3 | Completed |
| NCT00984867 | Phase 3 | Completed |
Competing Products
20 competing products in Heart Failure, Diastolic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| IV Loop Diuretics | Nuwellis | Pre-clinical | 15 |
| Stepped pharmacologic care | Nuwellis | Phase 3 | 69 |
| IV Loop Diuretics (LD) | Nuwellis | Pre-clinical | 15 |
| TRV120027 + Normal Saline | Trevena | Phase 1 | 25 |
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| TRV120027 + Placebo | Trevena | Phase 1/2 | 33 |
| Ilofotase alfa + Placebo | AM-Pharma | Phase 2 | 44 |
| INXN-4001 | Precigen | Phase 1 | 28 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| SGLT2i, beta blocker, ARNI, MRA, MTD | Eli Lilly | Approved | 85 |
| Pactimibe, CS-505 | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks | Daiichi Sankyo | Approved | 85 |
| olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil | Daiichi Sankyo | Phase 3 | 77 |
| Olmesartan | Daiichi Sankyo | Phase 3 | 77 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| Advagraf + Prograf | Astellas Pharma | Phase 2 | 52 |
| FK506E | Astellas Pharma | Phase 3 | 77 |